×
About 423 results

ALLMedicine™ Intermediate Uveitis Center

Research & Reviews  144 results

Corticosteroid implants for chronic non-infectious uveitis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841887
The Cochrane Database of Systematic Reviews; Reddy A, Liu SH et. al.

Jan 17th, 2023 - Uveitis is a term used to describe a group of intraocular inflammatory diseases. Uveitis is the fifth most common cause of vision loss in high-income countries, with the highest incidence of disease in the working-age population. Corticosteroids a...

Management of presumed trematode-induced granulomatous intermediate uveitis.
https://doi.org/10.1038/s41433-022-02336-4
Eye (London, England); Amin RH, Abdullatif AM

Dec 9th, 2022 - To describe the surgical management of presumed trematode-induced granulomatous intermediate uveitis (PTIGIU) not responding to medical treatment in controlling the inflammation. A prospective, interventional, single-center study in which patients...

A review of patient-reported outcome measures used in uveitis.
https://doi.org/10.1016/j.survophthal.2022.11.004
Survey of Ophthalmology; Senthil MP, Simon S et. al.

Nov 18th, 2022 - We review patient-reported outcome measures (PROMs) used to evaluate the quality of life (QoL) in uveitis and provide a quality assessment of the psychometric properties of the PROMs, making it easier to choose the best questionnaire for uveitis. ...

Comparison of pediatric patients with idiopathic uveitis, and uveitis due to juvenile i...
https://doi.org/10.1080/00325481.2022.2133853
Postgraduate Medicine; Gezgin Yıldırım D, Hasanreisoğlu M et. al.

Oct 11th, 2022 - The aim of this study is to compare the demographic, clinical features, treatment results and outcomes in pediatric patients with idiopathic uveitis and uveitis due to juvenile idiopathic arthritis (JIA) and Behçet's disease (BD). 97 pediatric uve...

CMV-related anterior and intermediate uveitis in a kidney transplant recipient treated ...
https://doi.org/10.1177/11206721221126308
European Journal of Ophthalmology; Morel A, Debieb AC et. al.

Sep 17th, 2022 - Belatacept is associated with a higher incidence of cytomegalovirus (CMV) disease and atypical presentations. Ocular manifestations are rare, representing up to 5% of disease manifestations and previous cases consisted in isolated retinitis. Herei...

see more →

Guidelines  1 results

Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tuber...
https://doi.org/10.1016/j.ophtha.2020.06.052
Ophthalmology Agrawal R, Testi I et. al.

Jul 1st, 2020 - The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, set up an international, expert-led consensus project to de...

see more →

Clinicaltrials.gov  15 results

Retrospective Comparison of the Efficacy of Methotrexate and Azathioprine as Background Treatment for Uveitis of Undetermined Origin: Single-centre Retrospective Study From 2005 to 2020
https://clinicaltrials.gov/ct2/show/NCT05370690

May 11th, 2022 - Uveitis is a major cause of ocular damage, responsible for 5 to 10% of blindness in the world. More broadly, up to 35% of patients with uveitis have visual acuity impairment ranging from "significant" to "legal blindness" [4]. The figures of "lega...

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
https://clinicaltrials.gov/ct2/show/NCT01124838

Jul 7th, 2021 - A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
https://clinicaltrials.gov/ct2/show/NCT03847272

Apr 13th, 2021 - Uveitis is characterized by inflammation of the uvea, which is the middle portion of the eye. The greatest challenge for the treatment of uveitis is patients who have inflammation involving the posterior segment, either primarily in the vitreous (...

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
https://clinicaltrials.gov/ct2/show/NCT02911116

Mar 26th, 2021 - Objective: Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects and many patients continue to experience d...

Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
https://clinicaltrials.gov/ct2/show/NCT02879084

Jan 27th, 2021 - Thirty six individuals (18 with anterior uveitis and 18 with intermediate uveitis) will be recruited at the Centre universitaire d'ophtalmologie du CHU de Québec. RNFL thickness will be measured with optical coherence tomography at 3 times. For an...

see more →

News  6 results

Two uveitis treatment options yield similar success
https://www.mdedge.com/rheumatology/article/207854/ankylosing-spondylitis/two-uveitis-treatment-options-yield-similar
Heidi Splete

Sep 10th, 2019 - Approximately two-thirds of adults with uveitis achieved inflammation control after 6 months on either methotrexate or mycophenolate alongside a reduction in corticosteroid use in an international, multicenter, open-label, randomized trial. “The f.

Sustained Drug-Delivery Tech Shows Promise
https://www.medpagetoday.com/ophthalmology/generalophthalmology/69384

Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.staging.medscape.com/viewarticle/865654

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.medscape.com/viewarticle/865654

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Grants Orphan Drug Status to Gevokizumab
https://www.medscape.com/viewarticle/769952

Aug 29th, 2012 - August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL-1β), for the treatment of noninfectious intermediate u...

see more →

Patient Education  3 results see all →